BioCardia, Inc. (BCDA) shares soared 48.13 percent, gaining $0.4423 to $1.3613 on Friday after the company announced that it received meeting minutes from the U.S. Food and Drug Administration confirming that its ongoing CardiAMP Heart Failure II Trial may support a Premarket Approval application for the CardiAMP Cell Therapy System in patients with ischemic heart failure with reduced ejection fraction (HFrEF).
The stock is currently trading at $1.3613, compared with its previous close of $0.9190 on the Nasdaq. During the session, it opened at $1.1950 and traded between $1.0800 and $1.8000. Trading volume surged to 126.24 million shares, dramatically exceeding its average volume of 164,233 shares.
The FDA feedback represents a significant regulatory milestone, as PMA is the agency's most rigorous approval pathway for high-risk medical devices. The company noted that the completed CardiAMP HF clinical data could serve as the first of two trials supporting a future PMA submission.
BioCardia shares have traded between $0.8400 and $2.4500 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.